暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股市场个股详情
IHE iShares安硕美国医药ETF
- 64.830
- -0.200-0.31%
收盘价 05/02 16:00 (美东)
65.360最高价64.750最低价
65.360最高价64.750最低价1.98万股成交量65.360今开65.030昨收128.49万成交额0.19%换手率--市盈率(静)1020.00万总股本69.27552周最高--市净率6.61亿流通值55.01452周最低0.91股息TTM1020.00万流通股69.275历史最高1.40%股息率TTM0.94%振幅21.642历史最低64.954平均价1股每手
分时
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
资金分布
单位: --
资金流向
实时日周月
暂无数据
新闻
由于减肥药物更新，调整了指导方针，安进股价上涨了13％
Viatris 将参加 BofA Securities 2024 年医疗保健会议
全球医疗保健公司维亚特里斯公司（纳斯达克股票代码：VTRS）今天宣布，该公司将参与美国银行证券2024年医疗保健...
为什么 Zoetis 股票在周四上涨了近 6%
安进公布的第一季度财务业绩好于预期后，该公司股价走高。此外，该公司还宣布向Royalty Pharma支付5000万美元的里程碑式付款。
安进公布的第一季度财务业绩好于预期后，该公司股价走高。此外，该公司还宣布向Royalty Pharma支付5000万美元的里程碑式付款。
辉瑞期权聚焦：5月2日成交34.57万张，未平仓合约332.41万张
美东时间5月2日，$辉瑞(PFE.US)$期权成交活跃，当日期权总成交量达34.57万张，其中看跌期权占总成交量的46.28%，看涨期权占53.72%。数据显示，截至当日收盘，$辉瑞(PFE.US)$未平仓合约（即没有买卖或行权的期权合约）总计约332.41万张，与其近30交易日均值比为108.26%。值得注意的是，在$辉瑞(PFE.US)$成交价格为27.54美元时，出现一笔看跌期权的异动大单，
快讯 | Arrowhead Pharmicals Inc——根据2022年与Royalty Pharma签订的协议，Arrowhead还有资格从Royalty Pharma获得1.1亿美元
评论
My long term investment review
Which fund investment themes are you bullish on? Do you have any specific fund(s) in mind?
Are you looking at a specific industry/market/asset type? Why?
What is your latest fund investment plan? What are the reasons behind it?
The current macro conditions (high inflation, FED rate hike and recession) have crippled our will to invest in long term. In my previous post, I reveal plan to invest in long term to position myself when the economy recover hopefully by ...
Are you looking at a specific industry/market/asset type? Why?
What is your latest fund investment plan? What are the reasons behind it?
The current macro conditions (high inflation, FED rate hike and recession) have crippled our will to invest in long term. In my previous post, I reveal plan to invest in long term to position myself when the economy recover hopefully by ...
11
10
专栏Weekly FDA Drug Pipeline Calendar (Oct 10- Oct 13)
Announcement Document
$艾伯维公司(ABBV.US$: AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022
$Protagonist Therapeutics(PTGX.US$: Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
$PTC Therapeutics(PTCT.US$: Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
$Scholar Rock(SRRK.US$: Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
Follow for more insights and top news for pharmacy industry!
$医疗保健精选行业指数ETF-SPDR(XLV.US$$SPDR标普制药指数ETF(XPH.US$$iShares安硕美国医药ETF(IHE.US$
$艾伯维公司(ABBV.US$: AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn's Disease and Ulcerative Colitis at the UEG Week 2022
$Protagonist Therapeutics(PTGX.US$: Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
$PTC Therapeutics(PTCT.US$: Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
$Scholar Rock(SRRK.US$: Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
Follow for more insights and top news for pharmacy industry!
$医疗保健精选行业指数ETF-SPDR(XLV.US$$SPDR标普制药指数ETF(XPH.US$$iShares安硕美国医药ETF(IHE.US$
15
1
阅读更多